MedPath

'Steps to your healthy future' programme evaluatio

Not Applicable
Completed
Conditions
Type 2 diabetes
Nutritional, Metabolic, Endocrine
Non-insulin-dependent diabetes mellitus
Registration Number
ISRCTN20770401
Lead Sponsor
niversity of Birmingham (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
292
Inclusion Criteria

1. Patients with a diagnosis of T2D for >1 year and <10 years
2. Patients between the ages of 18 and 70 years
3. Patients with an HbA1c level >7 and <11
4. Patients who commit to attend all of the programme and data collection sessions
5. Patients who are able to give informed consent

Exclusion Criteria

1. Patients who are currently pregnant
2. Patients who cannot read and write in English
3. Patients who are not capable of moderate physical activity
4. Patients who have participated in a research study investigating medical products in the previous 6 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluate whether the Steps 12-month education programme delivered to a population with established T2D (>12 months <10 years duration) can yield a reduction in HbA1c levels of = 0.6%, which represents a clinically significant change in glycaemic control, at 12 months post-baseline.
Secondary Outcome Measures
NameTimeMethod
Evaluate whether the Steps 12-month education programme delivered to a population with established T2D (>12 months <10 years duration) can yield improvements in biomedical measures (to include Cholesterol (Total, HDL, LDL), Blood Pressure, BMI, Weight, Waist, hip and neck circumference), psychosocial measures (to include Learning style preference, Quality of life , Diabetes-related distress, Depression presence and severity, Diabetes self efficacy, Diabetes knowledge , Perceived social support, Readiness to change), and lifestyle outcome measures (to include Smoking status, Alcohol intake, Physical activity, Dietary intake) at 3, 6 and 12 months post baseline session.
© Copyright 2025. All Rights Reserved by MedPath